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Abstract
Type 2 diabetes mellitus is a growing, worldwide public health concern. Recent growth has been particularly dramatic in the
states of The Co-operation Council for the Arab States of the Gulf (GCC), and these and other developing economies are at
particular risk. We aimed to systematically review the quality of control of type 2 diabetes in the GCC, and the nature and
efficacy of interventions. We identified 27 published studies for review. Studies were identified by systematic database
searches. Medline and Embase were searched separately (via Dialog and Ovid, respectively; 1950 to July 2010 (Medline), and
1947 to July 2010 (Embase)) on 15/07/2009. The search was updated on 08/07/2010. Terms such as diabetes mellitus, non-
insulin-dependent, hyperglycemia, hypertension, hyperlipidemia and Gulf States were used. Our search also included
scanning reference lists, contacting experts and hand-searching key journals. Studies were judged against pre-determined
inclusion/exclusion criteria, and where suitable for inclusion, data extraction/quality assessment was achieved using a
specifically-designed tool. All studies wherein glycaemic-, blood pressure- and/or lipid- control were investigated (clinical
and/or process outcomes) were eligible for inclusion. No limitations on publication type, publication status, study design or
language of publication were imposed. We found the extent of control to be sub-optimal and relatively poor. Assessment of
the efficacy of interventions was difficult due to lack of data, but suggestive that more widespread and controlled trial of
secondary prevention strategies may have beneficial outcomes. We found no record of audited implementation of primary
preventative strategies and anticipate that controlled trial of such strategies would also be useful.
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Introduction
The Type 2 Diabetes Mellitus problem
Diabetes mellitus is a chronic disease characterised by insufficient
insulin production and/or insulin resistance. Through its various
complications and a widespread high prevalence [1], diabetes
mellitus is a major contributor to morbidity and mortality world-
wide. Insulin resistance with a relative or real insulin deficiency is
the hallmark of type 2 diabetes mellitus. Over the last 3–4 decades,
the prevalence of type 2 diabetes has risen dramatically across the
world [2,3]. It currently accounts for over 90% of all diabetes cases
[4]. Various factors including population growth, ageing, continued
urbanisation and lifestyle modifications encouraging sedentary
lifestyles and obesity, will lead to further increases in prevalence.
Diabetes is a major public health issue, carrying huge societal and
economic, as well as personal, costs and risks. This has been
acknowledged by the United Nations through Resolution 61/225
(2006), which issued a call for Member States to implement
strategies to address the burden of diabetes in their societies.
Type 2 diabetes in the Gulf region
The states of The Co-operation Council for the Arab States of
the Gulf (GCC) exhibit some of the highest rates of type 2 diabetes
in the world. Five of the International Diabetes Federation’s ‘top
10’ countries for diabetes prevalence in 2010 and in 2030 are
projected to be in this region [1]. The anticipated prevalences for
diabetes 2010–2030 in the Gulf countries are: United Arab
Emirates (UAE) 18.7–21.4%, Kingdom of Saudi Arabia (KSA)
16.8–18.9%, Bahrain 15.4–17.3%, Kuwait 14.6–16.9% and
Oman 13.4–14.9% [1]. The recent and rapid socio-economic
development of the GCC countries has been associated with this
rising prevalence. The International Diabetes Federation suggests
that even in the absence of further economic development (that is,
based on changes in population demography alone), the number
of people with diabetes in its Middle East-North Africa region will
increase 94% from 2010 to 2030. Only the Sub-Saharan African
region is expected to see a greater increase in the number of cases
of diabetes (98%) during this period [1].
Responding to the type 2 diabetes problem
Many countries have responded to the concerns about type 2
diabetes by producing and implementing national diabetes
programmes (at the suggestion of the World Health Assembly,
aided and monitored by the International Diabetes Federation).
The International Diabetes Federation suggests Oman, Kuwait
and Bahrain have all implemented national diabetes programmes
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diabetes programme in Qatar) [1]. The UAE, however, published
national guidelines in 2009 [5]. We have not been able to
determine that the KSA has a national programme, but note that it
produces by far the greatest research output on diabetes. For all
countries, the extent and timings of programme implementation are
unclear, and in many cases the content of the programmes also.
Although the IDF suggests various dimensions that a national
diabetes programme would ideally include, there are no particular
suggestedstandardsinanyofthesethemes[1].Althoughthisreflects
theneedforlocallytailoredprogrammes,itperhapsalsoreflectsthat
there are no standardised desired clinical outcomes, even in
relatively well-studied populations. Both the extent and efficacy of
current diabetes management in the GCC region is thus unknown.
Review aims
The aim of this review was to examine the current quality of
management of type 2 diabetes in the member states of the GCC.
Unchecked, the chronic hyperglycaemia of diabetes is associated
with various adverse macro- and micro- vascular outcomes.
Glycaemic-, blood pressure- and lipid- control were used as
indicator outcomes as they are relatively well established correlates
of adverse vascular sequelae; preliminary searches suggested these
were relatively frequently considered outcomes; and they are widely
incorporated into national guidelines e.g. [6,7,8]. We aimed to,
wherever possible, specify results according to age and gender, as
evidence indicates that age/gender specified sub-populations with
specific disease prevalences and characteristics or severity may exist,
and thus that these populations may benefit from differential
management strategies. Due to the heterogeneity of studies iden-
tified on preliminary searching, there was no anticipated meta-analysis.
Methods
Ethical approval was not needed as this study was a systematic
review, with no primary data collection.
Review questions
A systematic literature search was carried out to identify
information relevant to the following review questions:
1. How good is current control of type 2 diabetes in the GCC
region, based on glycaemic-, blood pressure- and lipid- control
indicators?
2. Have implemented strategies (including public health/preven-
tative strategies) improved management of type 2 diabetes in
GCC countries?
Search
We developed a systematic review protocol (available from the
authors on request) using the Centre for Reviews and Dissemi-
nation guidelines [9]. The Medline and Embase databases (via
Dialog and Ovid, respectively; 1950 to July 2010 (Medline), and
1947 to July 2010 (Embase)) were searched separately on 15/07/
2009 and the search was updated on 08/07/2010. The search was
carried out using terms identified from PICOS deconstruction of
the above review questions, and database- and manually- derived
alternatives (see Appendix S1). Keywords used in the search
strategies reflected the quality of management of type 2 diabetes
and blood pressure, lipids and glucose in the GCC such as diabetes
mellitus, non-insulin-dependent, hyperglycemia, hypertension,
hyperlipidemia and Gulf States. The search strategy (available
from the authors on request) was trialled, reviewed by independent
professional colleagues (E.H, K.P), and updated (on 02/02/2010)
before use. Further relevant studies were identified by searching
the reference lists of the database-derived papers, contacting
expert investigators, screening conference proceedings including
those of The International Conference on Recent Advances in
Diabetes Mellitus and Its Complications 2006 and Gulf Research
Meeting 2010, citation searching and hand searching the available
online contents of the International Journal of Diabetes and
Metabolism and the Saudi Medical Journal, between the periods
1993–2009 and 2000–2010, respectively.
Selection
The search yielded 788 studies. The titles and abstracts
were evaluated by one reviewer to determine eligibility for full
screening. Studies that utilised designs from a pre-determined list
of acceptable methods - including randomized controlled trial and
observational study (cross sectional, quasi-experimental and
interventional) - were included. All studies wherein glycaemic-,
blood pressure- and/or lipid- control were investigated (clinical
and/or process outcomes) were eligible for inclusion. In addition,
any study describing primary preventative measures was eligible.
No limitations on publication type, publication status, study design
or language of publication were imposed. However, we did not
include secondary reports such as review articles without novel
synthesis. The inclusion criteria demanded that the study popu-
lation be people with diabetes (at least predominantly type 2;
unless a study relating to primary prevention), and of a GCC
country. All ages, sexes and ethnicities were included, resident and
expatriate populations, urban and rural, of all socioeconomic and
educational backgrounds. General population studies and studies
at all healthcare levels were included. 33 studies were identified as
suitable for full review, and were each considered by 2 reviewers. 6
studies were excluded, by consensus, either because data were not
(fully) available, or because the reporting left us unable to assess,
sufficiently, study quality (see Figure 1 and Figure S2).
Data extraction/quality assessment
The data captured for each study included data relating to, (1)
methods (study design, recruitment, measurement tools, analysis),
(2) participant characteristics, (3) setting, and (4) outcomes (those
observed, their definitions, results of analysis, length of follow-up).
Study quality was assessed using a checklist adapted from the
Centre for Reviews and Dissemination guidelines (see Appendix
S2) [9]. Data extraction was performed, in duplicate, by two
reviewers. Any disagreements were resolved by discussion with a
third reviewer. Refer to Fig S1.
Data synthesis
Data synthesis included summarising the results of the data
extraction process, considering the strength of evidence relating to
each of our questions, and examination of results inconsistent with
our formed proposals. Synthesis was limited by the numbers of
studies, particularly in consideration of the identified quasi-
experimental studies (see ‘Results’), and thus for this set of data,
description and discussion suffices.
Results
We identified 27 journal-published studies for review: 21 cross-
sectional and 6 quasi-experimental studies.
1. Cross-sectional studies
The cross-sectional studies included one undertaken in 1988/
1989, 2 in the 1990s, the remainder from 2000 onwards. The
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Oman [1]. In all but one study, wherein subjects with diabetes
were identified through a general population screening [20],
studies were carried out in primary care or hospital environments.
All involved retrospective review of patient records, and a very
small minority included a prospective component. Identification of
individuals with diabetes was in all cases by previous diagnosis. In
some cases, diagnosis of type 2 diabetes was specified, otherwise
the populations were mixed diabetic populations of predominantly
type 2 diabetes. Sample size ranged from 30–1236.
We identified 15 studies of each of glycaemic- and blood
pressure- control, and 11 of lipid control. In all cases, the lack of
standardised targets for these outcome measures was reflected in a
heterogeneous collection of definitions of control. Data that would
allowcomparisonofsubgroup outcomeswere generallynotavailable.
Glycaemic control. The identified studies of glycaemic con-
trol [10–24] are summarised in Table S1. One study investigated
process measures alone (although several additional studies
included these). 12/15 studies that reported clinical outcomes
considered glycosylated haemoglobin A1c (HbA1c) levels, 6/15
fasting blood glucose (one fasting blood glucose as a sole measure),
and 3/15 ‘post-prandial’ blood glucose levels (one post-prandial
glucose and fasting blood glucose alone).
With regard to clinical outcomes, target levels of HbA1c were
almost always ,7%, whereas the definition of ‘poor control’ was
more variable, but generally more than at least 8%. ‘Good control’
by fasting blood glucose and post-prandial blood glucose were
,7 mmol/l and ,9 mmol/l, respectively. Fasting blood glucose
.8 mmol/L and post-prandial glucose .10/11 mmol/L were
considered ‘poor control’. Process measures variably required
documentation of fasting blood glucose/HbA1c testing within the
study period, or within the previous 6 or 12 months.
Consistently, ,50% of patients achieved target glycaemic
control (e.g. HbA1c: ,7% were achieved in: 20.6% [16]; 45%
[17]; 33.3% [20]; 31.1% [22]; 27% [23]; 24% [24]). A group of
privately-treated patients in KSA, wherein 60.9% achieved
HbA1c ,7% (cf. 11.5% in government hospital-treated patients)
was an exception [21]. Plotting the values across time, there was
no obvious indication of recently improving/declining control.
Process measures were less commonly investigated, and of variable
outcome (0.4–98% achieved).
Blood pressure control. The identified studies of blood
pressure control [10,12,15,17–20,22–29] are summarised in Table
S2. One study considered only process measures. Three studies
provided only rates of hypertension (of variable definition) as an
outcome. The remainder provide (at least) rates of ‘well-controlled’
blood pressure, of more consistent definition. Rates of poor blood
pressure control were reported as either:
1. A basic record of ‘current’ rates of hypertension, or
2. Documentation of all (cumulative) rates of treated and
untreated hypertension
There may therefore be discrepancies where hypertension
assessment is not standardised and where cases of well-controlled
hypertension exist. This hinders comparisons already complicated
by differential lengths of diabetes diagnoses. It seems clear,
however, that blood pressure targets, however described by the
study authors, are far from met. The ,130/,80 mmHg or
,130/,85 mmHg targets were met in between 6.8% and 32% of
patients with a history of hypertension, and between 14.2 and
42.1% of the remaining samples, with one exception. Target blood
pressure was met in 83% of the sample of Afandi et al [17].
Rates of hypertension – of both cumulative and non-cumulative
measures, and of various criteria (see Table S2) – were frequently
Figure 1. Flow chart study selection process.
doi:10.1371/journal.pone.0022186.g001
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tation of blood pressure checks suggested they were rigorously
carried out, with almost 100% documentation of blood pressure
measurement achieved.
Dyslipidaemia. The identified studies of lipid control
[10,12,15,17–20,22–24,30] are summarised in Table S3. Again
process outcomes were of varied definition and infrequently
studied, but where investigated, documentation of measurement
within the previous year was achieved in 97% [17], 93% [20],
87% [19] and 14% [23]. The latter outlying result is from the most
recent study, where large proportions of people with diabetes had
not been screened for diabetes complications and/or cardiova-
scular risk factors in the previous 12 months. Unfortunately, the
exact cause of the low documentation was not determined as the
study did not test the compliance of people with type 2 diabetes to
regular screening.
The definitions of dyslipidaemia used were variable and utilised
various aspects of the lipid profile. Low density lipoprotein was the
most commonly used clinical outcome, with a consistently applied
target of ,2.6 mmol/L. This was met in approximately 30–50%
of patients, including in the cases of populations being entirely
with or entirely without a history of dyslipidaemia [24]. High
density lipoprotein, total cholesterol and triglyceride levels were
also used as measures of lipid control. Thresholds for dyslipidae-
mia were not consistent, yet where each indicator was used in
isolation, rates of dyslipidaemia were: 27.9% [10], 30% [10], 72%
[30], 63% [30], 44.6% [15], 44.6% [15], 76.4% [22] and 59.9%
[22].
2. Quasi-experimental studies
The 6 quasi experimental studies identified [31–36] are
summarised in Table S4. The studies were carried out between
1998 and 2007. There were 2 Saudi studies, 3 from the UAE, 1
from Kuwait. The study interventions included implementation of
newly-designed diabetes clinics/services, or use of a flow sheet to
guide management. There was no public health or primary
preventative aspect to any of the interventions.
All studies were based in primary care, and based on
populations previously diagnosed with diabetes. The samples are
likely to contain a predominance of type 2 diabetes patients,
except that of Udezue et al [33], which is likely to include a large
proportion of type 1 diabetes patients (based on age at diagnosis).
Where reported, the mean durations of diabetes diagnoses were
several years.
The outcomes monitored were generally concerned with
adherence to implemented guidelines, but three studies also
monitored some clinical outcomes, including glycaemic control,
throughout their duration. Generally, interventions successfully
increased compliance with clinical guidelines and improved
clinical outcomes, where monitored, over the duration of the
study. The studies were followed up for periods of 1 year [36], 18
months [31,35], 2 years [32], and 4 years [33,34] post-inter-
vention. Unfortunately, there are major limitations with all these
studies. Only one study [31] included a control population, and in
this case the physicians involved in writing the guidelines for the
developed intervention were largely from the intervention group.
Discussion
We found management of type 2 diabetes in the GCC region –
based on glycaemic-, blood pressure- and lipid- control indicators
– to be suboptimal. Almost universally, fewer than 50% of patients
meet targets for these clinical outcomes. There were no clear
differences between primary and secondary or tertiary care
(although possibly blood pressure was better controlled in hospital
settings).
The reviewed intervention studies were largely uncontrolled,
and thus difficult to interpret. All strategies reviewed here did
appear to improve outcomes, but involved multiple interventions
and are likely to have been carried out against a background of
evolving healthcare. No intervention studied included a primary
preventative dimension.
Although we rate the quality of type 2 diabetes management in
the GCC region as ‘poor’, the outcomes are similar to those
reported from elsewhere. Due to the disparity in genetic and
environmental contexts, type of health system, differences in inter-
vention methods and management guidelines and target thresh-
olds, we do not intend to suggest that any particular intervention
method is similarly efficacious across regions. Nevertheless, we
noted that for both clinical- and process- outcomes, similar results
are reported for other countries in the region such Lebanon [37]
and Egypt [38,39,40]. In comparison with a selection of reports
from various levels of healthcare in the UK [8,41,42], USA
[43,44] and Australia [45], clinical outcomes in the GCC countries
were generally lower, but this was not always so. Lipid control
[8,43,44] and blood pressure control [43,44,45] were most fre-
quently potentially comparable between these non-GCC countries
and the studies reviewed here, but Grant et al [44] also report a
34% attainment of HbA1c levels ,7%, which would be consistent
with a number of the results from the GCC region. Notably, of the
non-GCC region studies mentioned, this study includes perhaps
the highest proportions of patients under relatively high level care.
Although it may therefore underestimate outcomes more generally
achieved, it may in fact be a better comparator for the mixed
populations included in our review. We note also that in many
cases the outcomes of our reviewed studies would satisfy the upper
thresholds of the UK Quality and Outcomes Framework targets
[8].
With regard to process measures, these were generally well met
in all settings, but probably more so in the non-GCC developed
regions, particularly for glycaemic control. Finally, and impor-
tantly, we note that with regard to intermediate outcomes of
diabetes control, there has been evident progress in at least the UK
and USA [8,42,43], which we have not observed here to be the
case in the GCC region.
Limitations of study
A major limitation on the strength of our conclusions lies in the
heterogeneity of the reviewed studies. They were of varied
populations, reported on variable outcome measures, were from
various levels of healthcare provision and different countries
(although were predominantly from some and notably did not
include all GCC countries). Our outcomes of review are therefore
necessarily of only a broad nature, and as expected, they were not
appropriate for use in synthesis of outcomes with estimates of
confidence.
All of our reviewed studies were published in English. Overall,
the clarity of reporting in the reviewed papers was considered
relatively low; considered so as it often hampered assessment of
study quality. In a few cases, we excluded studies due to an
inability to sufficiently assess study quality (see Fig. 1). Otherwise,
we did not exclude studies based on quality, but noted some major
limitations, particularly in the intervention studies. With regard to
the cross-sectional studies, the relatively low numbers of papers
returned by each search led to difficultly identifying inconsistencies
versus widening accepted value ranges and extent of possible
effects, and in turn difficulty considering the strength of our final
proposals. Nevertheless, we feel the data are sufficient that we
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care in the GCC region.
Implications
We believe – based on the mentioned studies from non-GCC
countries and the intervention studies reviewed here – that the
standards of diabetes care in the GCC region can be improved.
Both of these sets of studies suggest that improved adherence to
process measures would improve clinical outcomes. In defining
these desired process outcomes, and the mechanisms to comply, it
may be useful to consider some of the interventions implemented
in the reviewed intervention studies. These could potentially be as
effective as those implemented elsewhere, and there is a degree of
overlap. For example, the use of patient education programmes,
diabetes specialist nurses and self-glucose monitoring appear to be
potentially useful and are relatively well developed components of
systems elsewhere. Continued auditing of these and other
interventions will be important. Standardising both the process
and clinical measures for clinical use and for auditing would be
useful to facilitate comparisons, although this has yet to be
achieved elsewhere, and fixing standards may be difficult. A review
of potentially useful and realistic standards for this region has not
been achieved and would be helpful.
We also consider that there is a large role for primary
prevention programmes in any new management strategy. It is
unclear whether or not any such intervention has been trialled in
this region, and a concerted/wide-reaching programme is
probably essential for feasibility and success of diabetes manage-
ment. Finally, we have not considered strategies likely to produce
changes in diabetes management without being aimed specifically
towards this (e.g. those implemented as part of the World Health
Organization ‘Innovative Care for Chronic Conditions Frame-
work’ adaptations in health systems associated with the shift
towards management of chronic rather than acute diseases [46]),
but it is anticipated that such changes will also be an important
part of managing the diabetes burden in the GCC region.
Conclusions
To our knowledge, this study is the first to systematically review
the quality of diabetes care in the GCC region. We found
management of type 2 diabetes, as indicated by three major
intermediate outcome measures (glycaemic control, blood pressure
and lipid profile), to be sub-optimal in the GCC countries. In
addition, we found that in many of the reviewed studies, there
were quality issues that impacted on their usefulness. We thus feel
attention to the management of diabetes in this region needs to be
improved, and that enhanced management must include better
quality of research and production of valuable data.
With regard to specific management strategies, we have here
reviewed several studies of interventions, which suggest a number
of secondary prevention strategies that may help in raising the
quality of management in this region. However, other forms of
intervention – particularly primary prevention strategies, which
have not been clearly implemented or audited – are also likely to
be useful. We anticipate that co-ordinated implementation of
locally-successful/targeted strategies may be particularly effective.
Continued, high quality review of all forms of interventions in the
GCC states would also be desirable.
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